Definition
There is no official definition of microdosing. A 2026 review in Expert Opinion on Pharmacotherapy described it as using about a quarter to a half of the manufacturer's starting dose, or stretching the time between doses. The term is borrowed from other fields and is used loosely online. It differs from titration, the step-by-step dose increase written into each FDA label.
Reasons people give
People and clinicians who describe microdosing give several reasons. Some want fewer stomach side effects. Some want a lower monthly cost. Others use it to keep weight off after reaching a goal, or for hoped-for effects on inflammation or general health. Commentaries also link the trend to the GLP-1 drug shortages of 2022 to 2025.
Evidence
The FDA-approved labels for semaglutide and tirzepatide do not include microdoses, and the approval trials did not test them. Published reviews from 2026 say high-quality evidence is limited, with mostly case reports, surveys and record reviews. Benefits seen at standard doses cannot be assumed at much smaller ones. Reviews also raise questions about dose accuracy when a small amount is measured from a pen or vial. Early reports describe less nausea, better adherence and modest weight loss, but these reports were not designed to prove an effect.
The SURMOUNT-MAINTAIN trial, published in The Lancet in 2026, looked at a related but different question: whether adults who lost weight on tirzepatide could keep it off after lowering to the 5 mg dose. That trial used an approved dose, not a microdose.
Legal status
In the United States, licensed prescribers may use approved drugs off-label, meaning for a use or at a dose not listed on the label. The FDA regulates drug products and their labeling, not the choices a doctor makes for an individual patient. Microdosing falls under the prescriber's medical judgment and is not an FDA-approved regimen.
Compounded products
Much of the microdosing discussion involves compounded semaglutide and compounded tirzepatide, which come in vials that allow custom amounts. Compounded drugs are prepared by state-licensed pharmacies for an individual prescription and are not FDA-approved products. Any dose is set by the prescriber. Programs that offer compounded semaglutide are compared on our compounded semaglutide page.
See also
References
- Beck and Clements, Expert Opin Pharmacother 2026 (microdosing commentary). pubmed.ncbi.nlm.nih.gov
- Panlilio et al., Cureus 2026 (GLP-1 microdosing narrative review). pubmed.ncbi.nlm.nih.gov
- Wegovy prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
- Trainer, J Am Assoc Nurse Pract 2026 (microdosing brief report). pubmed.ncbi.nlm.nih.gov
- Horn et al., Lancet 2026 (SURMOUNT-MAINTAIN). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.